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Abstract
AIM
To clarify the role of neoadjuvant concurrent chemo-
radiotherapy (NACCRT) followed by surgical resection 
for localized or locally advanced perihilar cholan-
giocarcinoma (CCA).
METHODS
We retrospectively reviewed 57 patients who under-
went surgical resection with or without NACCRT for 
perihilar CCA; 12 patients received NACCRT and 45 
patients did not received NACCRT. Patients with locally 
advanced perihilar CCA requiring NACCRT were defined 
as follows: (1) a mass involving unilateral branches of 
the portal vein or hepatic artery with insufficient volume 
of the anticipated remnant lobe; or (2) an infiltrating 
mass in the main portal vein that was too long for 
reconstruction, identified at preoperative staging. 
RESULTS
The median disease-free survival (DFS) durations of the 
neoadjuvant and non-neoadjuvant CCRT groups were 
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26.0 and 15.1 mo, respectively (P  = 0.91). The median 
overall survival (OS) durations of the neoadjuvant and 
non-neoadjuvant CCRT groups were 32.9 and 27.1 mo, 
respectively (P  = 0.26). The NACCRT group showed a 
downstaging tendency compared to the non-NACCRT 
group as compared with the tumor stage confirmed 
by histological examination after surgery and the 
tumor stage confirmed by imaging test at the time of 
diagnosis (P  = 0.01). 
CONCLUSION
NACCRT does not prolong DFS and OS in localized 
or locally advanced perihilar CCA. However, NACCRT 
may allow tumor downstaging and improve tumor 
resectability.
Key words: Klatskin tumor; Locally advanced; Survival 
rate; Neoadjuvant therapy; Chemoradiotherapy
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: This study is a retrospective study to clarify 
the role of neoadjuvant concurrent chemoradiotherapy 
(NACCRT) followed by surgical resection for locally 
advanced perihilar cholangiocarcinoma (CCA). The 
median disease free survival (DFS) durations of the 
neoadjuvant and non-neoadjuvant group were 26.0 
and 15.1 mo, respectively (P  = 0.91). The median 
overall survival (OS) durations of the neoadjuvant 
and non-neoadjuvant groups were 32.9 and 27.1 mo, 
respectively (P  = 0.26). However, the NACCRT group 
showed a downstaging tendency compared to the non-
NACCRT group (P  = 0.01). This paper will be helpful in 
the treatment plan for patients with locally advanced 
perihilar cholangiocarcinoma, especially NACCRT.
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3301-3308  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v23/i18/3301.htm  DOI: http://dx.doi.
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INTRODUCTION
Cholangiocarcinoma (CCA) is a group of tumor 
that arises from the intrahepatic, perihilar, or distal 
extrahepatic bile duct epithelial lining[1]. Among these 
diseases, perihilar CCA, commonly called Klatskin 
tumor, which develops from the right and/or left 
hepatic ducts at or near the biliary confluence is the 
most common, and accounts for around 70% of all 
CCA cases[2]. With advances in surgical technique, 
including aggressive liver resection, the indications 
of curative surgery for perihilar CCA have been 
broadened[3]. However, many cases are regarded 
as unresectable or locally advanced without distant 
metastasis. The common causes of unresectability for 
locally advanced perihilar CCA are anatomic proximity 
to major vessels, including the hepatic artery or portal 
vein, and combined atrophic or cirrhotic changes in the 
affected segment of the liver.
Recently, neoadjuvant concurrent chemoradio­
therapy (NACCRT) followed by liver transplantation 
has shown promising clinical outcomes in selected 
cases of perihilar CCA[4]. However, liver transplantation 
cannot be used as the standard treatment for all cases 
of locally advanced perihilar CCA because of the risk 
of recurrences, as well as a shortage of organ donors. 
Nevertheless, NACCRT is a promising therapeutic option 
for locally advanced perihilar CCA considering the 
meaningful outcomes of NACCRT in liver transplantation 
and borderline resectable pancreatic cancer[4,5].
Herein, we analyzed the clinical outcomes of NACCRT 
with curative resection of perihilar CCA in locally ad­
vanced stage.
MATERIALS AND METHODS
Patient population
From January 2004 to December 2013, 98 patients 
with perihilar CCA underwent surgery at Severance 
Hospital, Yonsei University College, Korea. Of the 98 
patients, 12 with locally advanced non­metastatic 
perihilar CCA received NACCRT. Patients with locally 
advanced perihilar CCA requiring NACCRT in this 
study were defined as follows: (1) a mass involving 
unilateral branches of the portal vein or hepatic artery 
with insufficient volume of the anticipated remnant 
lobe; or (2) an infiltrating mass in the main portal 
vein that was too long for reconstruction, identified 
at preoperative staging. Twelve patients had Bismuth 
type Ⅲ or Ⅳ and TNM stage Ⅲ or Ⅳ disease. Of 
the remaining 86 patients, 45 had the same disease 
stage as those who received NACCRT. In this study, 
patients with locally advanced perihilar CCA who 
received NACCRT were defined as the NACCRT group. 
Of the 57 patients, 31 underwent biopsy at the time of 
diagnosis and 26 did not undergo biopsy. Among the 
31 patients who underwent biopsy, 13 were diagnosed 
as adenocarcinoma and the remaining 18 were sus­
pected of cancer. In analysis of the tissues obtained 
from the operation, 55 patients were adenocarcinoma. 
Of 57 patients, 2 patients with no remnant cancer 
cell were adenocarcinoma in the biopsy performed at 
the time of diagnosis. In result, all of the 57 patients 
were adenocarcinoma, which was confirmed by biopsy 
performed at diagnosis or surgery. These patients 
received NACCRT followed by surgery, and adjuvant 
treatment as needed. Patients with locally advanced 
perihilar CCA who did not receive NACCRT were 
defined as the non­NACCRT group. They underwent 
surgery immediately after diagnosis and received 
adjuvant treatment as needed. Patients who needed 
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biliary decompression at the time of diagnosis had 
undergone procedures such as endoscopic retrograde 
biliary drainage (ERBD) or percutaneous transhepatic 
biliary drainage (PTBD). 
Clinical, radiologic, histopathologic, and survival 
data were retrieved up to December 2015 from a 
database at Severance Hospital, and were analyzed 
retrospectively. All of the laboratory data checked 
at the time of diagnosis and clinical stages, such as 
Bismuth classification and TNM stage before surgery, 
pathologic TNM stage, resection margin of surgical 
specimen, and microvascular/perineural invasions after 
surgery were analyzed in both groups. In the NACCRT 
group, the chemotherapy regimen, total radiation 
dose, complications during NACCRT, and response to 
NACCRT were analyzed.
This retrospective study was reviewed and approved 
by the institutional review board of Severance Hospital 
(IRB 2016­2480­001) and was conducted in accordance 
with the Declaration of Helsinki. Patient consent was 
waived owing to the retrospective nature of the study.
Neoadjuvant concurrent chemoradiotherapy regimen
In this study, 12 patients received NACCRT. Of 12 
patients, 5 patients received 5-fluorouracil (5-FU; 450 
mg/m2 per day, D1­4) and leucovorin (20 mg/m2 per 
day, D1­4) with external beam radiotherapy (1.8 Gy 
per day to a total dose of 50.4 Gy or 45 Gy). They 
received an average of 3.2 cycles of 5­FU/leucovorin. 
Of 12 patients, 5 patients received gemcitabine 
(1000 mg/m2 per day, D1, 8, 15, 22) with external 
beam radiotherapy (1.8 Gy per day to a total dose 
of 50.4 Gy or 45 Gy). They received an average of 
1.6 cycles of gemcitabine. Of 12 patients, 1 patient 
received gemcitabine (1000 mg/m2 on D1, 8, 15, 22) 
and cisplatin (70 mg/m2 on D1) with external beam 
radiotherapy (1.8 Gy per day to a total dose of 50.4 
Gy). He received one cycle of gemcitabine/cisplatin. 
Of 12 patients, 1 patient received Tegfur/Uracil (UFT; 
daily) with external beam radiotherapy (1.8 Gy per 
day to a total dose of 45 Gy).  
Follow-up duration
The survival of all 57 patients was analyzed. In cases 
of death, the date of death was investigated. In cases 
of survival or follow­up loss, the last follow­up date 
was investigated. Overall survival (OS) was defined 
from the date of diagnosis to the date of death, or to 
the date of the last follow­up. Disease free survival 
(DFS) was defined from the operation date to the date 
when recurrence was confirmed using imaging.
Statistical analysis
Continuous variables were summarized and reported 
as means with standard deviations or medians and 
interquartile ranges. Categorical variables were 
summarized and reported as frequencies and per­
centages. Statistical analyses were performed with a t 
test or χ 2 test, as appropriate. Significance was defined 
at a two­sided p­value of < 0.05. Survival analyses for 
DFS and OS were performed using the Kaplan­Meier 
method. Univariate and multivariate analyses were 
performed using the Cox proportional hazards model. 
Analyses were performed using the SPSS statistics 
software version 21 (IBM Corporation, Armonk, NY)
RESULTS
The baseline characteristics of patients are listed 
in Table 1. The median age of patients in the 
neoadjuvant group was lower than that of the non­
neoadjuvant group (neoadjuvant group, 59.0 years 
vs non­neoadjuvant group, 67.0 years; p = 0.02). 
However, when the patients were divided by age 
using 60 years as a cut­off, the numbers of patients 
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Table 1  Patient characteristics  n  (%)
Neoadjuvant 
chemoradiotherapy 
(n  = 12)1
Non-neoadjuvant 
chemoradiotherapy 
(n  = 45)1
P  value2
Demographic variables
Age (yr) 59.0 (48.25, 62.75) 67.0 (60.00, 69.00)    0.02
   Age ≥ 60 6 (50.0) 35 (77.8)    0.08
Sex (Male) 8 (66.7) 24 (53.3)    0.41
Follow-up 
duration (mo)
31.9 (19.8, 53.8) 26.4 (14.5, 42.1)    0.27
Laboratory variables
   Albumin (g/dL)   3.75 (3.450, 4.075) 3.60 (3.200, 3.850)    0.32
   Total bilirubin 
   (mg/dL)
2.3 (0.60, 8.45) 6.4 (2.35, 11.40) < 0.05
CA 19-9 (U/mL)     181.8 (27.08, 1452.50) 210.0 (71.35, 976.00)    0.74
Cancer-related variables
Bismuth 
classification
   ⅢA   2 (16.7) 21 (46.7)    0.10
   ⅢB   3 (25.0) 2 (4.4)    0.06
   Ⅳ   7 (58.3) 22 (48.9)    0.56
Pre-op AJCC 7th 
stage
   ⅢA (T3N0M0)   8 (66.7) 23 (51.1)    0.34
   ⅢB (T1-3N1M0)   2 (16.7) 17 (37.8)    0.30
   ⅣA (T4N0-1M0) 1 (8.3) 3 (6.7) > 0.99
   ⅣB (T1-4N2M0) 1 (8.3) 2 (4.4)    0.52
Tumor 
differentiation
< 0.01
   Well 0 (0) 11 (24.4)
   Moderately 7 (58.3) 29 (64.4)
   Poorly 0 (0)   5 (11.1)
   Undetermined 5 (41.7) 0 (0)
Post-operative 
adjuvant 
treatment
5 (41.7) 27 (60.0)    0.26
Recurrence 10 (83.3) 31 (68.9)    0.48
   OP site   3 (30.0) 11 (35.5)
   Liver   2 (20.0) 3 (9.7)
   Distant organ   3 (30.0)   9 (29.0)
   Carcinomatosis   2 (20.0)   8 (25.8)
1Continuous variables were denoted median (Q1, Q3) and categorical 
variables were denoted number (%); 2P values were determined using a 
Mann-Whitney test for continuous variables and a χ 2 test (Fisher’s exact 
test, Pearson and Mantel-Haenszel χ 2 test) for categorical variables. CA19-9: 
Carbohydrate antigen 19-9; AJCC: American Joint Committee on Cancer.
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between the 2 groups, and the proportion of well­
differentiated tumors in the non­NACCRT group was 
higher (p < 0.01). Of the patients who underwent 
adjuvant treatment after surgery, there were 5 (41.7%) 
in the NACCRT group and 27 (60.0%) in the non­
NACCRT group (p = 0.26). Tumor recurrence occurred 
in 10 patients (83.3%) in the NACCRT group and in 31 
patients (68.9%) in the non­NACCRT group (p = 0.48). 
Moreover, post­operative site recurrence was the most 
common in each group [NACCRT group, 3 (30.0%); 
non­NACCRT group, 11 (35.5%)]. 
The DFS estimates for the 2 treatment groups are 
shown in Figure 1. The median DFS durations of the 
NACCRT and non­NACCRT groups were 26.0 and 15.1 
mo, respectively (p = 0.91). The OS estimates for the 
2 treatment groups are shown in Figure 2. The median 
OS duration of the NACCRT and non­NACCRT groups 
were 32.9 and 27.1 mo, respectively (p = 0.26). 
Various chemotherapy regimens were used for 
NACCRT, as listed in Table 2. Of the 12 patients, 
5 (41.7%) received 5­fluorouracil + leucovorin, 5 
(41.7%) received gemcitabine, and 1 of the remaining 
2 patients received gemcitabine + cisplatin and the 
other 1 tegafur/uracil (UFT). All 12 patients received 
3­dimensional (3D) conformal radiotherapy using 
CCRT. The median dose of radiotherapy was 5040 cGy 
(range, 4545 to 5040). Three (25%) patients showed 
toxicities related to CCRT. The most common toxicities 
were nausea and vomiting (66.7%). No treatment­
related deaths occurred. Two (66.7%) patients showed 
neutropenia and anemia higher than grade II, which 
delayed the treatment. When abdominal computed 
tomography (CT) scans were compared before and 
after NACCRT, and confirmed using the Response 
Evaluation Criteria in Solid Tumors (RECIST) 2.0, 7 
(58.3%) out of 12 patients had a partial response (PR) 
and 5 (41.7%) out of 12 patients had a stable disease 
(SD).
Table 3 shows the efficacy of NACCRT. The NACCRT 
group showed a decrease in tumor stage after surgery 
above and below 60 years of age were similar in the 
2 groups [neoadjuvant group, 6 (50.0%) vs non­
neoadjuvant group, 35 (77.8%), p = 0.08]. There 
were no significant differences in sex or follow­up 
durations between the 2 groups [sex (male patient)]; 
neoadjuvant group, 8 (66.7%) vs non­neoadjuvant 
group, 24 (53.3%), p = 0.41; follow­up durations, 
neoadjuvant group, 31.9 mo vs non­neoadjuvant 
group, 26.4 mo, p = 0.27. Total bilirubin levels 
(neoadjuvant group, 2.3 vs non­neoadjuvant group, 
6.4; p < 0.05) was higher in the non­neoadjuvant 
group. However albumin and carbohydrate antigen 
19­9 (CA 19­9) levels were no significant difference 
between the 2 groups. There was no difference in 
the distribution of Bismuth type and TNM stage 
between the 2 groups because they were selected. 
All CCAs included in this analysis were histologically 
adenocarcinoma. Five cases were classified as 
undetermined for tumor differentiation, as shown in 
Table 1. Of these 5 cases, 2 surgical specimens had 
no detectable cancer cells and 3 pathologic records of 
tumor differentiation were not recorded. There was a 
difference in the distribution of tumor differentiation 
Table 2  Summary of neoadjuvant chemoradiotherapy  n  (%)
Neoadjuvant chemoradiotherapy 
(n  = 12)
Regimen of chemotherapy
   5-fluorouracil + leucovorin   5 (41.7)
   Gemcitabine   5 (41.7)
   Gemcitabine + cisplatin 1 (8.3)
   Tegfur/Uracil (UFT) 1 (8.3)
Total dose of radiotherapy (cGy) 5040 (4545, 5040)1
Response in follow-up image
   Partial response 7 (58.3)
   Stable disease 5 (41.7)
   Complete response in pathology 2 (16.7)
   Downstaging of TNM stage 4 (33.3)
Toxicity
   ≥ Grade Ⅱ 2 (16.7)
1Continuous variables were denoted median (Q1, Q3) and categorical 
variables were denoted number (%).
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Figure 1  Disease-free survival rate curves of the 2 treatment groups. DFS 
rate was performed with using the Kaplan-Meier method.
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Figure 2  Overall survival rate curves of the 2 treatment groups. OS rate 
was performed with using the Kaplan-Meier method.
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compared with preoperative tumor stage [downstaging 
in the NACCRT group, 11 (91.7%) vs downstaging in 
the non­NACCRT group, 23 (51.1%), p = 0.01]. Ten 
patients (83.3%) in the NACCRT group and 30 (64.4%) 
in the non­NACCRT group underwent margin­negative 
resection (R0 resection) (p = 0.32). Microvascular 
invasion [NACCRT group, 6 (50.0%) vs non­NACCRT 
group, 29 (64.4%), p = 0.51] and lymph node 
metastasis [NACCRT group, 3 (25.0%) vs non­NACCRT 
group, 25 (55.6%), p = 0.06] showed no significant 
difference between the 2 treatment groups. Perineural 
invasion was more frequent in the non­NACCRT group 
[NACCRT group, 7 (58.3%) vs non­NACCRT group, 44 
(97.8%), p < 0.01]. Moreover, there were 2 patients 
(16.7%) with perioperative complications in the 
NACCRT group and 11 (24.4%) in the non­NACCRT 
group (p = 0.71). Of the 2 patients in the NACCRT 
group, 1 (50.0%) experienced small bowel obstruction 
due to post­operative adhesion and 1 (50.0%) 
experienced wound seroma. Of the 11 patients in the 
non­NACCRT group who experienced postoperative 
complications, 4 (36.4%) developed septic shock due 
to wound infection, 2 (18.2%) experienced wound 
infection, 1 (9.1%) had wound dehiscence, 1 (9.1%) 
had a catheter infection, 1 (9.1%) developed septic 
shock due to aspiration pneumonia, 1 (9.1%) had a 
liver abscess, and 1 (9.1%) experienced liver failure. 
However, there was no death due to perioperative 
complications in both 2 groups. 
DISCUSSION
Several studies have already reported the role of 
NACCRT in CCA. Some studies have shown the role of 
neoadjuvant therapy in allowing downstaging surgery 
for unresectable cancer. McMasters et al[6] described 
9 patients, 5 with perihilar and 4 with distal common 
bile duct CCA, who were treated with preoperative 
chemoradiotherapy. Of the 9 patients, 3 experienced a 
pathologically complete response. The rate of margin­
negative resection was 100% for the preoperative 
chemoradiotherapy group compared with 54% for 
the surgery alone group. Moreover, there was no 
patient who experienced any significant treatment­
related complications during preoperative treatment. 
Nelson et al[7] identified a cohort of 12 patients out of 
45 with both proximal and distal extrahepatic CCAs 
who underwent NACCRT. Of these 12 patients, 10 had 
initially unresectable disease and 2 had resectable 
disease. As a result, 11 out of the 12 patients in the 
neoadjuvant group underwent R0 resection, and 3 
achieved a complete pathological response. 
As described above, the potential advantages of 
neoadjuvant chemoradiotherapy include the delivery 
of therapy with an intact vascular supply, downstaging 
of borderline resectable tumors, a reduction of tumor 
seeding and locoregional dissemination during surgery, 
and selection of patients for surgery according to their 
response to therapy[8]. 
In our study, the response evaluation of NACCRT 
through comparison abdominal CT scans was 7 
patients PR and 5 patients SD. Furthermore, 2 
(16.7%) out of 12 patients had a pathologically 
complete response. The follow­up image, which is 
usually performed and evaluated not only by the 
patients in this study but also by the usual CCRT, 
was performed one month after the completion of 
NACCRT. In two cases, the main lesions treated with 
CCRT were observed as residual mass due to post­
CCRT inflammation and evaluated as partial response 
and stable disease through RECIEST. As another 
result of our study, 4 out of 12 patients achieved 
tumor downstaging due to downgrade of T stage by 
receiving NACCRT. Furthermore, there was a tendency 
of downstaging in the NACCRT group compared to 
the non­NACCRT group. To evaluate the tendency to 
downgrade the stage of the two groups, we compared 
the clinical stage at diagnosis and the postoperative 
pathological stage. Obviously, the clinical TNM stage 
and pathological TNM stage may be different. Even 
considering this point, the NACCRT group tends to 
downstage more than the non­NACCRT group. If a 
large number of data is analyzed, this tendency can 
be confirmed more clearly. There was no significant 
difference in the performance of margin­negative 
resection between the 2 treatment groups [NACCRT 
group, 10 (83.3%) vs non­NACCRT group, 30 (66.7%); 
p = 0.32]. Reduction of metastasis to lymph nodes 
was expected to be an advantage of neoadjuvant 
therapy; however, it did not show a meaningful result 
[NACCRT group, 3 (25.0%) vs non­NACCRT group, 25 
(55.6%), p = 0.06].
In addition, in our study, NACCRT did not show 
any results that could ultimately improve the cure 
rate by lowering the cancer stage to an operable state 
Table 3  Efficacy of neoadjuvant chemoradiotherapy  n  (%)
Neoadjuvant 
chemoradiotherapy 
(n  = 12)
Non-neoadjuvant 
chemoradiotherapy 
(n  = 45)
P  value1
Alteration of TNM 
stage before and 
after surgery 
   0.01
   Upstaging 0 (0) 11 (24.4)
   No change 1 (8.3) 11 (24.4)
   Downstaging 11 (91.7) 23 (51.1)
R0 resection 10 (83.3) 30 (66.7)    0.32
Surgical pathology
   Microvascular 
   invasion
6 (50.0) 29 (64.4)    0.51
   Perineural 
   invasion
7 (58.3) 44 (97.8) < 0.01
   Lymph node 
   metastasis
3 (25.0) 25 (55.6)    0.06
Perioperative 
complications
2 (16.7) 11 (24.4)    0.71
1P values were determined using a Mann-Whitney test for continuous 
variables and a χ 2 test (Fisher’s exact test, Pearson and Mantel-Haenszel χ 2 
test) for categorical variables.
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(OS of the NACCRT group, 32.9 mo vs OS of the non­
NACCRT group, 29.8 mo, p = 0.26). Similar results 
were also found in other studies[6,7]. In particular, the 
aim to reduce recurrence through locoregional control, 
one of the objectives of NACCRT, was not seen in 
this analysis (DFS of the NACCRT group, 26.0 mo vs 
DFS of the non­NACCRT group, 15.1 mo, p = 0.91). 
Locoregional recurrence or distant recurrence occurs in 
spite of margin­negative resection, which has already 
been confirmed through other studies and highlights 
the need for adjuvant treatment[9,10]. In our study, we 
analyzed predicting variables for DFS and OS (Tables 
4 and 5). The postoperative adjuvant treatment 
group showed a decreased risk compared with non­
postoperative adjuvant treatment about DFS; however, 
there was no statistical significance (HR = 0.78, 
95%CI: 0.42­1.45, p = 0.43). In addition, adjuvant 
therapy was performed with lymph node metastasis 
or margin­positive resection. Of the neoadjuvant 
group, 5 patients received chemotherapy after surgery 
for adjuvant therapy. Of the regimens for adjuvant 
therapy, 3 patients received Fluorouracil/Cisplatin 
and 2 patients received Gemcitabine/Cisplatin. Of 
the non­neoadjuvant group, 19 patients received 
chemotherapy, 5 patients received radiotherapy and 
3 patients received concurrent chemoradiotherapy 
after surgery for adjuvant therapy. Of the regimens 
for adjuvant therapy, 6 patients received Fluorouracil/
Cisplatin, 3 patients received Gemcitabine/Cisplatin, 
3 patients received Gemcitabine, 2 patients received 
UFT, 1 patient received Tegafur (TS­1)/cisplatin, 
1 patient received Tegfur/uracil (UFT)/Cisplatin, 1 
patient received Fluorouracil/Carboplatin and 1 patient 
received Fluorouracil/leucovorin/oxaliplatin (FOLFOX).
Other predicting variable for DFS and OS in our 
study was serum CA19­9 level. Serum CA19­9 level 
is a well­known prognostic marker of CCA[11,12]. In 
addition, there is a conclusion that CA19­9 is the 
independent risk factor for recurrence after curative 
resection in biliary tract cancer[13] as well as the staging 
system including preoperative CA19­9[14]. These results 
including our study suggest that CA19­9 is sufficient 
marker for predicting prognosis as well as marker 
for tracking cancer recurrence. However, the value of 
CA19­9 is known to be influenced by cholestasis[15], 
Table 4  Univariate analysis for identifying the risk factor for disease free survival and overall survival
Disease-free survival Overall survival
HR(95%CI)    P value1    HR (95%CI)    P value1
Male > 1.00 (0.54-1.87) < 1.00     1.34 (0.75-2.41)    0.33
Age < 60    1.20 (0.61-2.36)    0.59     0.86 (0.46-1.61)    0.63
Bismuth type
   ⅢA 1.00 1.00
   ⅢB    1.95 (0.70-5.42)    0.20     1.07 (0.31-3.63)    0.92
   Ⅳ > 1.00 (0.52-1.95)    0.99     0.84 (0.47-1.51)    0.56
Pre-op AJCC 7th stage
   ⅢA 1.00 1.00
   ⅢB    0.86 (0.44-1.66)    0.64     0.88 (0.46-1.68)    0.70
   ⅣA    0.55 (0.13-2.37)    0.42     0.70 (0.21-2.34)    0.57
   ⅣB      2.51 (0.56-11.19)    0.23     2.43 (0.71-8.25)    0.16
Serum total bilirubin    0.76 (0.95-1.04)    0.76     1.01 (0.97-1.06)    0.66
Serum total bilirubin ≥ 3    1.21 (0.64-2.28)    0.56    1.40 (0.77-2.53)    0.27
Serum CA19-9       1.01 (> 1.00-1.01) < 0.01 > 1.00 (1.00-1.01)    0.13
Serum CA19-9 ≥ 300   3.28 (1.68-6.41) < 0.01    2.58 (1.39-4.78) < 0.01
Variation of CA19-9 after NACCRT   1.07 (0.98-1.15)    0.12    1.02 (0.95-1.10)    0.61
Received NACCRT   1.05 (0.51-2.15)    0.91    0.65 (0.30-1.39)    0.27
Performed R0 resection   1.01 (0.50-2.04)    0.98    0.61 (0.33-1.15)    0.12
Tumor differentiation
   Well 1.00 1.00
   Moderately  2.30 (0.95-5.55)    0.06    1.34 (0.63-2.83)    0.45
   Poorly    1.25 (0.15-10.47)    0.84      3.66 (1.08-12.33)    0.04
   Indeterminate    3.30 (0.92-11.88)    0.07    1.21 (0.37-3.97)    0.75
Microvascular invasion 1.37 (0.73-2.56)    0.33    1.89 (1.02-3.51)    0.04
Perineural invasion 0.58 (0.22-1.49)    0.25    1.35 (0.53-3.45)    0.53
Lymph node metastasis 1.01 (0.54-1.86)    0.98 > 1.00 (0.56-1.78)    0.99
Received adjuvant treatment 0.78 (0.42-1.45)    0.43    0.77 (0.43-1.36)    0.36
1P values were determined with a univariate Cox proportional hazards regression test. AJCC: American Joint Committee on Cancer; CA19-9: Carbohydrate 
antigen 19-9; NACCRT: Neoadjuvant concurrent chemoradiotherapy.
Table 5  Multivariate analysis for identifying the risk factor for 
disease-free survival and overall survival
Disease-free survival Overall survival
HR (95%CI) P  value1 HR (95%CI) P  value1
Serum CA19-9 ≥ 300 3.28 (1.68-6.41) < 0.01 2.66 (1.40-5.06) < 0.01
R0 resection 0.47 (0.24-0.90) 0.02
1P values were determined using a multivariate Cox proportional hazards 
regression test. CA19-9: Carbohydrate antigen 19-9.
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and it is known that the higher the pre­treatment 
value, the worse the prognosis[14,16]. Therefore, we 
conducted a univariate and multivariate analysis using 
a Cox proportional hazard model with a category of 
more than 3 mg/dL of total bilirubin (bilirubin ≥ 3) and 
more than 300 U/mL of CA19­9 (CA19­9 ≥ 300) based 
on the results of Kim et al[15]. In univariate analysis, 
CA19­9 ≥ 300 was identified as risk factor for DFS and 
OS. In addition, CA19­9 ≥ 300 was analyzed as an 
independent risk factor for DFS and OS in multivariate 
analysis including the effect of bilirubin ≥ 3. Although 
the outcome of surgery in the high CA19­9 group is 
known to be poor[17], the relationship between high 
CA19­9 and perioperative complications was not 
statistically significant in this study (p = 0.33; not 
listed in the table). However, the change of CA19­9 
by NACCRT was not a predicting variable for DFS and 
OS (DFS: HR = 1.07, 95%CI: 0.98­1.15, p = 0.12 
and OS: HR = 1.02, 95%CI, 0.95­1.10, p = 0.61). 
Another risk factor for OS in multivariate analysis was 
R0 resection (HR = 0.47, 95%CI: 0.24­0.90, p = 0.02). 
In univariate analysis, the effect of R0 resection on OS 
was not statistically significant, but it was confirmed as 
independent predictive variable in multivariate analysis. 
In fact, several studies have suggested R0 resection as 
the most important factor affecting prognosis[18­20].
Our study had some limitations that are inherent 
to a retrospectively designed study. There may be 
limitations in representing the effect of NACCRT in 
the NACCRT group because of the small number of 
patients and the variety of regimens used as NACCRT. 
For a more statistically significant comparison, we also 
considered the propensity match score. However, the 
number of study groups and control groups are small 
and limited. Controlling the two groups under similar 
conditions to compare only the use of NACCRT is 
expected that the number of subjects to be compared 
will be reduced and the statistical meaning will be 
insufficient. Nevertheless, the advantage of this study 
is that we set up a control group consisting of patients 
with disease of a Bismuth type and TNM stage similar 
to the locally advanced disease to determine the 
efficacy of NACCRT. 
NACCRT is thought to affect the downstaging 
of locally advanced stage perihilar CCA, which may 
increase the possibility of surgery. However, this analysis 
did not show an expected increase in DFS or OS as the 
possibility of surgery increased. In conclusion, NACCRT 
may be a feasible downstaging method to allow surgery, 
or an option as a bridging therapy during preparatory 
procedures for extended hepatectomy, such as portal 
vein embolization. In addition, systemic treatment, such 
as adjuvant chemotherapy, is also required for patients 
with perihilar CCA who do not have distant metastasis. 
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